Private equity firm Permira buys pharma service provider Ergomed in £703.1M deal

Private equity company Permira has acquired publicly-listed pharma service provider Ergomed in a cash agreement worth £703.1 million ($883 million), with the deal slated to become effective in the first quarter of 2024.

Miroslav Reljanović

“We believe the acquisition will significantly increase our ability to invest in our commercial infrastructure, technology transformation and to execute transformational M&A, in both the CRO and PV businesses,” said Ergomed founder Miroslav Reljanović.

Ergomed is a contract research company specializing in early-stage clinical drug trials and drug safety investigations in oncology, rare disease and other therapeutic areas. It became a listed company in the AIM market in 2014.

The deal outlines each Ergomed shareholder can receive £13.50 ($16.93) per share. Reljanović will be selling his 18% worth of shares in the company. Jefferies and Numis advised the deal.

Permira, which invests in technology, consumer and healthcare services, has CDMO Cambrex and healthtech company Althea in its portfolio.

contract research
cro
pharma
healthcare
private equity
shares